NCT01235416 - A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

February 28, 2010

Conditions

Histologically or Cytologically Documented Solid Tumors

Interventions

DRUG

AMG 706

In each of these 3 planned treatment cohorts, approximately 6 evaluable subjects will be treated with gemcitabine (1000-mg/m2 intravenously over 30 minutes, once weekly starting on day 1, week 1 of cycle 1) and erlotinib (100 mg orally once daily starting on day 1, week 1 of cycle 1)